Literature DB >> 8360817

Fluconazole in patients at risk from invasive aspergillosis.

R Kappe1, K J Osterziel, R Rüchel, S Siehl.   

Abstract

We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic. Fluconazole may obscure the onset of aspergillosis. We feel that it should neither be given prophylactically nor for fever of unknown origin in patients who are at high risk of contracting aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360817     DOI: 10.1080/02681219380000311

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  2 in total

Review 1.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

2.  An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy.

Authors:  B E de Pauw; J M Raemaekers; J P Donnelly; B J Kullberg; J F Meis
Journal:  Ann Hematol       Date:  1995-02       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.